PDCD1 and neoplasm: In 2017, Pinato et al. have for the first time reported the programmed cell death ligands expression in PHEOs/PGLs with a distinctive prognostic, clinic-pathologic and immuno-biologic role, thus suggesting a potential therapeutic role for PD-1/PD-L1 targeted checkpoint inhibitors in these tumours [20].